Hoth Therapeutics (HOTH) denied market rumors on Wednesday regarding plans to raise fresh capital.
The company said it has no plans for a public or private offering at this time. It also said it had over $10 million in cash and no debt -- enough funding to execute its strategic initiatives and advance its pipeline.
The company added that enrollment in the clinical trial of its lead therapeutic candidate HT-001 to treat rash and skin disorders associated with cancer therapy is "proceeding as planned."
Hoth Therapeutics shares were up more than 8% in recent trading.
Price: 2.48, Change: +0.20, Percent Change: +8.55
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。